Innoviva (INVA) Tax Provisions (2014 - 2026)
Innoviva's (INVA) quarterly Tax Provisions came in at $48.0 million in Q1 2026, up 499.6% YoY from $8.0 million in Q1 2025, and up 93.42% on a QoQ basis from $24.8 million in Q3 2025.
Innoviva (INVA) Tax Provisions (2014 - 2026) Analysis & Trends
Innoviva (INVA) has 11 years of Tax Provisions data on file, last reported at $48.0 million in Q1 2026.
- Quarterly Tax Provisions rose 499.6% year-over-year to $48.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.7 million (up 315.06% YoY) and the FY2024 annual result came in at $26.6 million, up 1757.15% from the prior year.
- Tax Provisions improved to $48.0 million in Q1 2026, from $24.8 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $63.1 million in Q3 2022 to a low of -$4.6 million in Q2 2024.
- A 5-year average of $15.2 million and a median of $8.6 million in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions surged 600.0% — and 2024, when it plunged 202.09%.
- Tracing INVA's Tax Provisions over 5 years: stood at $63.1 million in 2022, then slumped by 76.68% to $14.7 million in 2023, then tumbled by 34.72% to $9.6 million in 2024, then surged by 158.33% to $24.8 million in 2025, then surged by 93.42% to $48.0 million in 2026.
- The last three Tax Provisions figures came in at $48.0 million (Q1 2026), $24.8 million (Q3 2025), and $8.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -24.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.60 Mn |
| Mar 31, 2026 | 47.97 Mn |
| Sep 30, 2025 | 24.80 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Sep 30, 2024 | 9.60 Mn |
| Jun 30, 2024 | -4.59 Mn |
| Mar 31, 2024 | 8.60 Mn |
| Sep 30, 2023 | 14.71 Mn |
| Jun 30, 2023 | 4.50 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Sep 30, 2022 | 63.06 Mn |
| Jun 30, 2022 | -900,000.00 |
| Mar 31, 2022 | 6.86 Mn |
| Sep 30, 2021 | 65.60 Mn |
| Jun 30, 2021 | 25.33 Mn |
| Mar 31, 2021 | 19.70 Mn |
| Dec 31, 2020 | -44.69 Mn |
| Sep 30, 2020 | 8.90 Mn |
| Jun 30, 2020 | 19.89 Mn |